SBMA (spinal and bulbar muscular atrophy), also called Kennedy disease, is an X-chromosomal recessive adult-onset neurodegenerative disorder caused by death of the spinal and bulbar motor neurones and dorsal root ganglia. Patients may also show signs of partial androgen insensitivity. SBMA is caused by a CAG repeat expansion in the first exon of the androgen receptor (AR) gene on the X-chromosome. Our previous study suggested that all the Nordic patients with SBMA originated from an ancient Nordic founder mutation, but the new intragenic SNP marker ARd12 revealed that the Danish patients derive their disease chromosome from another ancestor. In search of relationships between patients from different countries, we haplotyped altogether 123 SBMA families from different parts of the world for two intragenic markers and 16 microsatellites spanning 25 cM around the AR gene. The fact that different SBMA founder haplotypes were found in patients from around the world implies that the CAG repeat expansion mutation has not been a unique event. No expansion-prone haplotype could be detected. Trinucleotide diseases often show correlation between the repeat length and the severity and earlier onset of the disease. The longer the repeat, the more severe the symptoms are and the onset of the disease is earlier. A negative correlation between the CAG repeat length and the age of onset was found in the 95 SBMA patients with defined ages at onset.
Introduction
SBMA (Spinal and Bulbar Muscular atrophy), also called Kennedy disease (MIM 313200), is an X-chromosomal recessive neurodegenerative adult-onset disorder in men. 1 bulbar muscular atrophy with fasciculations and generalised muscle weakness, frequently sensory symptoms, facial and perioral contraction fasciculation and dysarthria, dysphonia and dysphagia. These symptoms are caused by progressive death of the spinal and bulbar motor neurones and dorsal root ganglia. 3 Patients frequently show signs of partial androgen insensitivity with gynecomastia, impotence, testicular atrophy and reduced fertility. 4 SBMA is caused by a CAG repeat expansion in the first exon of the androgen receptor (AR) gene. 5 Patients have about twice as many CAG repeats as unaffected males, 38 ± 72 repeats, 6 ,7 compared with 10 ± 36 for unaffected males. 8 SBMA was the first disease in which a CAG repeat expansion was found. At least eight such diseases are known: Huntington disease, DRPLA (dentatorubral-pallidolyusian atrophy) and spinocerebellar ataxias SCA1, SCA2, SCA3, SCA6 and SCA7. 9 Trinucleotide diseases often show correlation between the repeat length and severity and earlier onset of the disease. The longer the repeat, the more severe the symptoms are and the earlier the onset of the disease. 10, 11 Most Finnish SBMA patients come from the district of Vaasa in Western Finland. 3 We have shown that all the Finnish families share identical alleles for at least five nearby markers around the AR gene. Because the majority of our patients were Swedish speaking, we extended the study to patients from the linguistically related neighbouring Scandinavian countries. The Finnish, Swedish, Norwegian and Danish SBMA families shared the same intragenic GGC allele, as well as similarities in allele distribution, which suggests a common origin for the Scandinavian SBMA mutation. There also seems to be a specific, more extended sub-founder haplotype in each country.
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Both in myotonic dystrophy (DM) 13, 14 and Friedreich's ataxia 15 a predisposing haplotype associated with long normal repeats explains the founder effects found in these diseases. This prompted us to include in the study SBMA patients from around the world to test whether a common founder haplotype is shared by patients from different countries.
Material and methods
The patient material consisted of 123 SBMA families with a total of 151 patients and 10 carriers from 10 different countries: Finland, Sweden, Norway, Denmark, Germany, Belgium, Italy, Japan, Australia and Canada ( Table 1 ). The patient material was collected through the neurologists from these countries. Blood samples were drawn after informed consent was obtained. The German patients were from two different hospital districts, as were the Australian patients. Families GI-GV came from Ulm, GVI-GXIII came from Saar, AI-AIX were from Sydney and AX-AXV from the Perth district. Japanese patients), the first symptom being any of the characteristic SBMA symptoms. The dependence between the CAG repeat length and the age at onset was examined using Spearman rank order correlation. The correlation was calculated for all the nationalities together and separately inside the countries.
The SBMA patients were haplotyped for the intragenic SNP marker ARd12 (Whitehead cSNP Data) (http://waldo.wi.mit. edu/cvar_snps/) that changes a cutting site of StuI restriction enzyme, the intragenic GGC repeat and 16 other microsatellite markers (DXS8062, DXS8032, ALAS2, DXS1213, DXS1194, DXS1111, DXS135, DXS1125, DXS981, DXS1689, DXS339, DXS106, DXS1216, DXS1275, DXS453, DXS1690) spanning a 25.2 cM region around the androgen receptor gene. The locations and distances 12 of the markers were obtained from The Genome Database (GDB) (http:// gdbwww.gdb.org/). The microsatellites were amplified by a standard PCR method.
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Results
The haplotypes of the patients are illustrated in Figure Table 2 .
In one family, JII, mosaicism was present in one of the two family members. Both JII family members carried 48 CAG repeats, but in one of them longer, up to 51 CAG repeats were also seen (Figure 1 ). Among the 95 SBMA patients with defined ages at onset a negative correlation between the CAG repeat length and the age of onset was found (R=70.30, P=0.0027) (Figure 2) . When the different countries were studied separately, a negative correlation was present only among the Japanese patients (R=70.60, P= 0.018). Such a correlation was not found among the Finnish (R=70.04, P=0.87), Swedish (R=0.05, P=0.91), German (R=70.16, P=0.60), Italian (R=70.17, P=0.36) or Canadian (R=70.07, P=0.83) patients.
Discussion
Before discovering the new intragenic SNP marker ARd12 (StuI site), it was concluded that all the Nordic patients with SBMA originated from an ancient Scandinavian founder haplotype. 12 However, the fact that the Danish patients carry the StuI site, which is absent in the Finnish, Swedish and Norwegian patients, revealed that at least the Danish patients derive their disease chromosome from another ancestor. The similar Finnish, Swedish and Norwegian SBMA haplotypes still indicate a common genetic background for SBMA patients in these three countries. Even though the difference between the Danish and the other Scandinavian haplotypes Figure 2 The negative correlation between the CAG repeat number and age at onset of SBMA. 16 it is unlikely that the SBMA mutation of these two countries was of the same origin, because of the dissimilarity of the extended haplotypes. All the German patients from Saar (GVI-GXIII) harboured a similar haplotype, and one of the patients from Ulm (GV1) carried a haplotype common to the patients from Saar. That is not very surprising, since these places are not far apart. The`Saar' and`Ulm' haplotypes harbour similar alleles in the intragenic markers, + allele for StuI and 17 GGC repeats, but the flanking markers DXS1194 and DXS1111, as well as most of the other microsatellite markers studied, are different in the patients from these two areas. Since all the German patients carry similar intragenic alleles, it is possible that the patients from Saar and Ulm have inherited a common ancestral mutation. The Belgian patient had a unique haplotype, also harbouring the intragenic StuI site and 17 GGC repeats. As this is the only sample from Belgium, the origin of this mutation cannot be estimated. The mutation, although unlikely, might have a common origin with the German patients, considering the geographical proximity. However, these intragenic alleles are very common, as StuI site is carried by about 85% (Whitehead cSNP Data) and 17 GGC repeats is found in about half of the control population. 12, 17 Therefore, the SBMA mutation is likely to have occurred more than once in an AR gene with the StuI site and 17 GGC repeats. The Italian patients showed three entirely different founder haplotypes with either 13, 17 or 18 intragenic GGC repeats, and thus the SBMA mutation in Italy has probably at least three different origins. The Japanese patients had two distinct haplotypes with 17 and 18 GGC repeats; thus the SBMA mutation has occurred at least twice, as previously indicated. 18 The Australian patients originated from two distinct areas, Sydney (AI1-AIX1) and Perth (AX1-AXV1), and two different founder haplotypes were found among them. The situation is, however, different from the Germans, since the two Australian founder haplotypes were carried equally by patients from both districts. All the Canadian patients carried different haplotypes, but two of them (CIV1 and CVIII1) harboured haplotypes similar to the two different Australian founder haplotypes. This is explained by the common immigration history of both these countries. This, along with the fact that the two Australian haplotypes were not dependent on hospital districts, suggests that the mutations have occurred in these haplotypes in Europe before the ancestors of these patients emigrated to different continents. The British settlement of Australia did not start until 200 years ago. 19 Also, the two Canadian patients with`Australian' haplotypes, CIV1 and CVIII1, are British by origin. The ethnic diversity of the Canadian samples is clearly shown by the lack of a common Canadian haplotype. Hence, the SBMA mutation has occurred in different haplotypes among each original population.
The dependence between the CAG repeat length and the severity and age at onset of SBMA is controversial. In two studies 10, 11 correlation between the repeat length and more severe symptoms and earlier onset of SBMA is reported, but in two other studies 20, 21 no correlation was found. In our study, weak negative correlation was found between the CAG repeat length and the age of onset in the 95 SBMA patients with defined ages at onset, but when the patients from different countries were examined separately, the correlation was detected only in the Japanese patients. The weakness of the correlation might be explained by the fact that our study did not include the largest extremes of repeats attainable in SBMA. The largest repeat included in the correlation dataset was 55 CAG repeats (JX), while repeats as long as 72 are reported in SBMA. 7 Estimating the age of onset in SBMA patients is not simple. The patient primarily becomes conscious of muscular atrophy, but the first symptoms may have occurred 5 ± 20 years before the patient consults a doctor because of muscular asthenia. Also, the progress of the disease is difficult to monitor because other symptoms caused by ageing intermingle with the symptoms of SBMA. There is no evidence of modifiers of clinical course in SBMA. The fact that so many different founder haplotypes have thus far been identified in SBMA patients from different countries implies that the CAG repeat expansion mutation is not a unique event. No particular expansion-prone haplotype could be detected, in contrast to myotonic dystrophy (DM) (CTG repeat disease) and Friedreich's ataxia (GAA repeat disease), in which a predisposing haplotype associated with long normal repeats has been reported. 13 ± 15 Founder effects are also found in other CAG repeat diseases, eg SCA1 in Japan, 22 SCA2 in Cuba, 23 Japan 24 and India, 25 MJD in Japan 26 and SCA6 in Germany. 27 As these studies considered only restricted geographical areas, the presence of a predisposing haplotype is not clear. Besides, the SCA2 studies 23 ± 25 revealed multiple founder haplotypes, indicating multiple origins for this disease. The CAG repeat in the AR gene is relatively stable, 28 which explains the predominance of many country-specific founder haplotypes. Still, the SBMA CAG repeat seems to have expanded several times in different populations.
European Journal of Human Genetics
SBMA around the world A Lund et al 435
